MedTrace Logo

Long-Term Follow-up Safety of Clonidine Micropellets

NCT03776318 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-10-06

No results posted yet for this study

Summary

Long-term follow-up study to evaluate the safety of clonidine micropellets up to 12 months post injection.

Conditions

  • Lumbosacral Radiculopathy

Interventions

DRUG

Long-Term Safety Follow-up

STX-015-18-01 long-term safety follow-up

Sponsors & Collaborators

  • Sollis Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher Gilligan, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2021-01-22
Completion
2021-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03776318 on ClinicalTrials.gov